Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA3 | P15088 | 3/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.51 |
| ▸ | CPA1 | P15085 | 2/20 | 0.51 |
| ▸ | CPB1 | P15086 | 1/20 | 0.51 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7609056 | 0.87 | CPA3 (0.53) | CPA3FOLH1ACENAALAD2 | |
| SCHEMBL29088272 | 0.83 | CPA3 (1.00) | CPA3CYP1A2FOLH1CPA1CPB1 | |
| SCHEMBL3963424 | 0.83 | CPA3 (1.00) | CPA3CYP1A2FOLH1CPA1CPB1 | |
| SCHEMBL7608459 | 0.82 | CPA3 (0.63) | CPA3CYP1A2FOLH1CPA1CPB1 | |
| SCHEMBL7350860 | 0.78 | CPA3 (0.71) | CPA3CYP1A2FOLH1CPA1 | |
| SCHEMBL7619620 | 0.78 | CPA3 (0.56) | CPA3CYP1A2FOLH1 | |
| SCHEMBL5051309 | 0.76 | CPA3 (0.67) | CPA3CYP1A2FOLH1CPA1CPB1 | |
| SCHEMBL17537902 | 0.76 | CPA3 (0.85) | CPA3CYP1A2FOLH1CPA1CPB1 | |
| SCHEMBL12494233 | 0.75 | CYP1A2 (0.83) | CPA3CYP1A2FOLH1CPA1CPB1 | |
| SCHEMBL6724759 | 0.75 | CYP1A2 (0.83) | CPA3CYP1A2FOLH1CPA1CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6265609-B1 | INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY; IN DRUGS TO TREAT GLUTAMATE ABNORMALITIES; COMPULSIVE DISORDERS AND PROSTATE DISEASES, TO EFFECT NEURONAL ACTIVITIES | GUILFORD PHARMACEUTICALS INC. | 2001-07-24 | — | — | US | claimed |
| US-6458775-B1 | N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) INHIBITORS ENZYME ACTIVITY, PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH INHIBITORS, AND METHODS OF THEIR USE TO INHIBIT NAALADASE ENZYME ACTIVITY, THEREBY EFFECTING NEURONAL | GUILFORD PHARMACEUTICAL INC. | 2002-10-01 | — | — | US | disclosed |
| US-6265609-B1 | INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY; IN DRUGS TO TREAT GLUTAMATE ABNORMALITIES; COMPULSIVE DISORDERS AND PROSTATE DISEASES, TO EFFECT NEURONAL ACTIVITIES | GUILFORD PHARMACEUTICALS INC. | 2001-07-24 | — | — | US | disclosed |